Pershing S, Talwar N, Armenti ST, et al. - In this retrospective analysis of treatment patterns, researchers ascertained if publication of Comparison of Age-related macular degeneration Treatment Trial (CATT) outcomes and introduction of aflibercept to the marketplace affected intravitreal bevacizumab and ranibizumab utilization. Of the 317 ophthalmologists predominantly administering ranibizumab to Medicare pre-CATT beneficiaries, 221 reduced post-CATT use of ranibizumab, while 96 continued to use ranibizumab ≥ 80% of the time. After CATT publishing, many ophthalmologists who favored ranibizumab moved to bevacizumab, while most of those who favored bevacizumab before CATT publishing continued to favor it later. The introduction of Aflibercept had little effect on ranibizumab or bevacizumab preferences.